Atopic Dermatitis Market

Global Atopic Dermatitis Market Size (2024 to 2032)

As per our research report, the global atopic dermatitis market size was valued at USD 13.47 billion in 2023 and is expected to grow at a CAGR of 14.5% from 2024 to 2032 and be worth USD 45.56 billion by 2032 from USD 15.42 billion in 2024.

Currently, the atopic dermatitis market is growing steadily. The market is also witnessing an increased launch or introduction frequency of new drugs or therapies in 2023-24. However, patients continue to fight to manage their moderate-to-severe form of atopic dermatitis with presently accessible treatments. Several experience inferior permanent disease control, and serious itch can considerably affect their everyday lives. Besides this, AD management shows major challenges because of its complicated pathophysiology consisting of genetic predispositions and immune dysregulation. On the other hand, standard or conventional treatments, like emollients and topical corticosteroids, remain primary, their restrictions have encouraged the development of unique pharmacological approaches.

Atopic dermatitis is an inflammatory skin disease, and its severity varies from patient to patient. It usually begins in childhood and is mainly confined to the flexural surfaces of the body. It is highly prevalent and is more commonly known as eczema. Itching, redness of the skin, cracking, weeping, etc., are symptoms, and it is a long-term disease. Low humidity, cold weather, and seasonal allergies are common causes, and the pattern of the disease and its severity determine the kind of treatment it ought to receive. The global atopic dermatitis market encompasses all aspects of the research, development, manufacturing, and commercialization of products and therapies to treat this condition.

MARKET DRIVERS

The growth of the atopic dermatitis market is propelled by its rising cognizance. It is calculated that a maximum of 30 per cent of patients whose AD was identified at the time of childhood will continue to have the disease all over adulthood. The increased availability of basic information over the Internet has primarily served as the driving the awareness about this disease. Moreover, the surging popularity of eHealth and digital technologies contributes to the expansion of the market. Additionally, the multiplying number of programs from governments around the world is anticipated to expand the market. This is reflected in the growing amount of research studies and product launches regarding the AD management. For instance, the incidence of this disease in India has elevated in the last 30 years, with about 5.9 per cent of grownups impacted.

The growing awareness of atopic dermatitis worldwide is driving the growth of the global market.

 Increasing awareness of AD people using herbal medicine, natural ointment, and ultraviolet therapy boosts the market. Medical institutions provide education about AD and its primary treatment at home. In addition, much research will find fast relief for the disease. All these factors drive the market forward. For instance, to bring awareness among European people about AD, World Atopic Eczema Day was initiated in 2018 to increase awareness of the condition internationally and around Europe through an initiative organized by the European Federation of Allergy and Airways Diseases Patient Associations (EFA) and the International Coalition of Dermatology Patient Organizations (Global Skin).

The launch of biologics & small molecules, premium-priced drugs substituting generic first-line and second-line therapeutics, and improved diagnostics are propelling the growth of the global atopic dermatitis market. Growing skin allergies and chronic disorders are expected to accelerate the market’s growth rate. Atopic dermatitis disease severity ranges from patient to patient, and the treatment procedures involve the severity degree. Escalating expenditure on healthcare and the growing popularity of these treatment procedures through digital advertisements accelerate the growth of the global atopic dermatitis market.

The growing government initiatives are offering possibilities to the market participants of the atopic dermatitis market.

Atopic dermatitis (AD), the leading cause of skin-related disease burdens worldwide, is rising in developing countries in Asia, Africa, Latin America, and the Middle East. Therefore, the governments of respected countries worldwide are taking initiatives to develop and bring awareness among the people about atopic dermatitis. For Instance, The Ministry of Health and Prevention, MoHAP, has recently signed a Memorandum of Understanding with the Sanofi Aventis Community and Axios Health Education Programs in which MoHAP will launch a new program named "Ea'nah" (Support) for patients with relapsed multiple sclerosis (RMS) and relapsed-remitting MS (RRMS), patients with mild to extreme eczema (atopic dermatitis) and patients with relapsed multiple sclerosis (RMS).

The growing number of initiatives from various governments is expected to expand the global atopic dermatitis market.

Furthermore, an increasing number of patients suffering from various skin disorders, changes in climatic conditions, and the rise in disposable income in both developed and developing countries are further expected to accelerate the market's growth rate. Besides, the emergence of the latest technologies in the medical sector and the introduction of innovative procedures magnify this market's growth. In addition, the growing incidence of atopic dermatitis in children is expected to boost the market.

MARKET RESTRAINTS

Patient hesitation and the side effects of medication or treatment are restricting the expansion of the atopic dermatitis market. Though TCS is effective, it is faced with patient reluctance because of the worries regarding rebound impacts, skin thinning, and steroid phobia. TCIs, such as pimecrolimus and tacrolimus, come with an alert owing to the risks of cancer, which restricts their application to second-line treatment. Moreover, systemic immunomodulators, like azathioprine, methotrexate, and cyclosporine, have been implemented for serious refractory disease, however, they come with considerable side effects. Hence, these are not FDA-permitted for AD.

The lack of skilled healthcare professionals is one of the biggest restraints to the global atopic dermatitis market.

Skilled healthcare personnel are in short supply in under-developing regions. Enough training programs are one of the primary reasons for this shortage. Hence, healthcare facilities often need more skilled doctors to meet the standards of care. The government could provide numerous workforce enticements to improve performance in public-sector hospitals and health centers. Various developed nations address a similar issue by basing reimbursement on capitation and a pay-for-performance model to balance the necessity of expanding service against budget restrictions.

Rising complications and side effects after the treatment procedure in some people hinder the global atopic dermatitis market growth.

In addition, oral medicine can have severe side effects when taken for a more extended period. Furthermore, the need for more skilled people in hospitals and clinics and fluctuations in economic strategies negatively impact the growth rate of the atopic dermatitis market. In addition, less availability of necessary equipment in rural areas remains challenging for the market players. Also, the high cost of treatment procedures due to advanced features is causing the growth rate of this market to decline.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Atopic Dermatitis Market Analysis By Treatment Type

The drug treatment segment is the bigger category in the atopic dermatitis market and its supremacy is believed to remain on the growth course over the estimation period. Market players are progressively investing in drug development with the US in the lead in this process. Moreover, the rising inclination from people and healthcare service benefactors to cure atopic dermatitis using drugs rather than radiation therapy and the growing incidence of initial diagnosis diseases are particularly driving segment market growth.

The drug treatment segment held the largest market share in 2023 and its domination of the segment is likely to continue during the forecast period. The growing preference from people and healthcare providers to treat atopic dermatitis with drugs instead of radiation treatment and the rising prevalence of early-diagnosis diseases are majorly propelling segmental growth. In addition, increasing investments by key market participants and R&D institutes to develop new and effective drugs for atopic dermatitis contribute to the segment's growth rate. Drugs are believed to be more effective in treating symptoms of atopic dermatitis, such as itching, redness, and inflammation. Due to this, the adoption of drug treatment is higher than that of radiation treatment. The wider availability and accessibility of drugs for atopic dermatitis for patients is another major attribute promoting segmental growth.

The radiation treatment segment is expected to grow at a rate of 14.6% during the forecast period owing to the growing adoption of radiation treatment procedures for patients with severe or widespread disease. In addition, the growing awareness regarding the benefits of radiation treatment among healthcare providers, such as being effective in reducing inflammation and itching and promoting the healing of the skin, are driving the adoption of radiation treatment.

Global Atopic Dermatitis Market Analysis By Distribution Channel

The retail pharmacies segment gained the top spot and is anticipated to expand during the forecast period for the atopic dermatitis market. This growth can be due to their convenience, availability, and cost-effectiveness for patients wanting OTC treatments and prescriptions. Moreover, the affordability of medicines accessible at retail stores adds considerably to their popularity. People generally discover that these pharmacies provide medications at competitive prices and discounts on frequent orders, positioning them as easier-to-follow treatment routines.

The topical segment is anticipated to hold a major market share of the global atopic dermatitis market and is also expected to grow at a high CAGR of 14.7% during the forecast period. Topic treatments are available in creams, ointments, lotions, and gels and are believed to reduce inflammation, itching, and skin dryness effectively. The growing preference from healthcare providers to prescribe medication in topical options for atopic dermatitis patients is majorly driving segmental growth.

However, the oral segment is also predicted to showcase a steady CAGR during the forecast period, and the growth of the oral segment in the global atopic dermatitis market is expected to be seen in the coming years. If the skin disease is in an advanced stage, most healthcare provider gives oral pills to help control the symptoms. In addition, at-home therapies use this oral medication for moderate to severe atopic dermatitis.

Global Atopic Dermatitis Market Analysis By Route of Administration

The topical segment is expected to be the leading atopic dermatitis market. It is generally used as the first-line treatment for handling this disease. To date, calcineurin inhibitors (TCI) and topical corticosteroids (TCS) are commonly considered the cornerstone of topical therapy in AD management. Moreover, this treatment can be implemented directly in the impacted areas, enabling dedicated relief without affecting the complete body. Further, several patients favour these therapies because of their reduced risk and convenience in systemic side effects against the oral route.

The retail pharmacies segment captured a significant share of the worldwide market in 2023 and is expected to grow at a high CAGR of 14.7% during the forecast period. Retail pharmacies are popular among patients as they are convenient and easily accessible, one of the key factors propelling the segment's growth rate.

During the forecast period, the hospital pharmacies segment captured a significant share of the global atopic dermatitis market owing to the growing flow of patients to hospitals and increasing patient preference to obtain medications from hospital pharmacies. In addition, people believe hospital pharmacies are a trustworthy destination to purchase prescribed medications, driving segmental growth.

On the other hand, the online pharmacies segment is also expected to grow steadily during the forecast period owing to the growing awareness among people regarding online pharmacies and increasing willingness from people to use online channels to buy healthcare products.

REGIONAL ANALYSIS

North America holds a commanding share of the atopic dermatitis market and is expected to record notable growth throughout the forecast period. The regional market is propelled by the significant prevalence of Eczema in the United States and Canada.

According to the National Eczema Association, almost 16.5 million grown-up people in the U.S. suffer from eczema, with 6.6 million having moderate-to-severe indications such as rashes, discoloration, skin, dry and scaly skin, and itchiness, which can result in more scratching that can lead to the skin to bleed and crack.

The North American market had a significant share of the global market in 2023 and is anticipated to register the lead during the forecast period. New product launches, early treatment adoption, and lifestyle changes are the reasons behind it. According to recent studies, forty percent of people in America are suffering from moderate to severe atopic dermatitis diseases and emotional burden in addition to pain, physical discomfort, and sleep disturbance for 16.8 million people in the US It is a skin disease that results in rashes and patches of itchy skin, mainly around the neck, face, and eyes. In addition, 18% of Canadians suffer from atopic dermatitis (AD). It is a visible skin disease that impacts the quality of life through depression, anxiety, and psychosocial issues. Health Canada has approved CIBINQO (abrocitinib) for treating atopic dermatitis patients aged 12 years and older. However, many Canadian AD patients want to connect with peers for further support and need mental health resources.

Globally, the European region is predicted to be the second-largest regional market during the forecast period. Heavy investment in R&D activities in this region is the cause of the observable trend mentioned above. As a result, European countries like Spain and the United Kingdom are expected to showcase promising growth from 2020 to 2025. Nearly 5 percent of German adults suffer from atopic dermatitis (AD). German people are using many treatments for these diseases. In addition to UV therapy and proactive topical therapy, the European guidelines for treating AD include reactive topical therapy for mild AD or temporary eczema and proactive topical therapy for moderate AD. German people have so many guidelines for treatment. Systemic drugs and phototherapy are used for skin diseases. Unfortunately, German patients still suffer from a high burden of disease and a low quality of life, indicating insufficient medication. 

The Asia Pacific region is predicted to be the fastest-growing global atopic dermatitis treatment market at a CAGR of 15.7% in the abovementioned forecast. India is forecasted to register the highest CAGR during the same period. This region extension can be attributed to victims' significant unmet clinical needs, increasing spending on healthcare, and adequate treatment availability. Indian Dermatology Expert Board Members have provided several guidelines for atopic dermatitis. In India, advanced drugs and treatments are provided for PD diseases. Several hospitals are adopting treatment for this disease as more people suffer from AD. This mainly occurred due to climate changes in India. The incidence of AD in China has rapidly increased during the past ten years. Most people aged 10-30 years suffer from these diseases requiring treatment. Chinese Society of Dermatology Immunology Group developed guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China. Rapid advances in diagnosing and treating AD in the past five years globally and in China will drive the market forward. AD is the second most common skin disease in Japan. In Japan, most children suffer from this disease. In 2021, the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved the CIBINQO drug, which is oral, for the treatment of moderate to severe atopic dermatitis (AD) in adults. Along with this, Moizerto® Ointment is also approved in Japan and is manufactured by Otsuka Pharmaceutical Co., Ltd. for people suffering from atopic dermatitis in 2021.

The Latin American market is expected to grow significantly in the next five years due to a rapidly growing population, changing lifestyles, and a paradigm shift towards Western lifestyles; increasing R&D and a large target patient pool are attributable to the observable trend mentioned above. As per the reports, 8 percent of adults suffer from AD in Brazil. The causes of PD in Latin American countries are tropical, temperate, and cold temperatures, humidity, pollution, ultraviolet rays, average time spent indoors, and allergen exposure.

The MEA region is anticipated to grow sluggishly in the abovementioned forecast period.

KEY PLAYERS IN THE ATOPIC DERMATITIS MARKET

Companies playing a leading role in the global atopic dermatitis market include Novartis International AG, Sanofi, Pfizer, AbbVie Pharmaceuticals Pvt Ltd, Bausch Health Cos., Inc., Bristol-Myers Squibb Corporation, Regeneron Pharma, Viatris Incorporation, LEO Pharma, and Dermavant Sciences.

RECENT HAPPENINGS IN THE MARKET

• In September 2024, Eli Lily and Company press released the approval of EBGLYSS (lebrikizumab-lbkz) by the U.S. Food and Drug Administration (FDA). This gives a new primary biological therapy for a moderate-to-serve form of atopic dermatitis that fails to achieve adequate control with topical agents.
• In August 2024, experts from the Beijing University of Chinese Medicine (i.e. Siqing and colleagues) revealed that the consumption of vitamins, including retinol, carotene, vitamin E, and Vitamin C, can potentially lower the threat of atopic dermatitis.

DETAILED SEGMENTATION OF THE GLOBAL ATOPIC DERMATITIS MARKET INCLUDED IN THIS REPORT

This market research report on the global atopic dermatitis market has been segmented and sub-segmented based on treatment type, route of administration, distribution channel, and region.

By Treatment Type

• Drug Treatment
• Radiation Treatment

By Route of Administration

• Topical
• Oral

By Distribution Channel

• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa